A PHASE I/II, RANDOMISED, SINGLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-ASCENDING-DOSE
STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF
AZD9550 MONOTHERAPY AND CO-ADMINISTRATION OF AZD9550 AND AZD6234 IN PARTICIPANTS
LIVING WITH OBESITY AND OVERWEIGHT WITH OR WITHOUT TYPE 2 DIABETES MELLITUS
- Registry ID
- D8460C00002
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA AB
- Start date
- 2025-09-15
- Last update
- 2025-08-20
Conditions
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY {VESPER 6)
- A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ELECOGLIPRON COMPARED WITH ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS (ELUMINATE-2)
- A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF ALN-6222 IN ADULT PARTICIPANTS WITH OBESITY
- A CLINICAL STUDY TO COMPARE EFFICACY AND SAFETY OF TWO DIFFERENT DOSES OF CAGRISEMA AND SEMAGLUTIDE IN PARTICIPANTS WITH OBESITY WITH OR WITHOUT TYPE 2 DIABETES
- EFFICACY AND SAFETY OF NNC0487-0111 COMPARED TO PLACEBO ON MORBIDITY AND MORTALITY IN PEOPLE WITH HEART FAILURE WITH PRESERVED OR MILDLY REDUCED EJECTION FRACTION AND OBESITY (HF-POLARIS)
- EFFICACY AND SAFETY OF NNC0487-0111 S.C. ONCE-WEEKLY IN PARTICIPANTS WITH OBESITY (AMAZE 1)
View on source registry